Novartis on course to set new highs
20/02/24 -"Considering the strong operational performance and a meaningful progress for the late-stage pipeline in recent years, we have revised upwards our NAV estimates by c.10%."
Pages
71
Language
English
Published on
20/02/24
You may also be interested by these reports :
07/02/25
The Q4 operating profitability was somewhat ahead of the street’s expectations, though sales lagged the consensus by c.2%. Moreover, the 2025 outlook ...
06/02/25
The Q4 results exceeded the street’s expectations, while the 2025 outlook was in line with consensus estimates. Moreover, the firm raised its ...
06/02/25
The Q4 sales were ahead of the consensus, though operating profits were somewhat behind the street’s expectations. Also, a better-than-expected 2025 ...
05/02/25
The Q4 earnings were ahead of consensus estimates, driven by a robust showing across key focus areas. Moreover, the 2025 outlook was better than the ...